On Nov 22, major Wall Street analysts update their ratings for $Kura Oncology (KURA.US)$, with price targets ranging from $18 to $34.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and adjusts the target price from $35 to $29.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $32.
Jefferies analyst Roger Song maintains with a buy rating, and adjusts the target price from $32 to $28.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Kura Oncology (KURA.US)$'s main analysts recently are as follows:
Kura Oncology has entered a significant development and commercialization agreement with a major partner for its prime project, ziftomenib. The deal, which includes a substantial upfront payment alongside notable near-term milestones, provides Kura with a solid financial foundation to pursue pivotal frontline development. This strategic partnership allows for an extensive and aggressive development plan for ziftomenib, notably in the treatment of acute myeloid leukemia, at a critical period to maximize its commercial potential. Additionally, this agreement mitigates financial risks associated with the company's stock in the short to medium term, while preserving considerable value.
Following Kura Oncology's announcement of a global strategic alliance with Kyowa Kirin for the development and commercialization of ziftomenib, an oral menin inhibitor aimed at treating acute myeloid leukemia and other hematologic malignancies, analysts interpret this deal as strategically advantageous. It provides essential capital to expedite Kura's AML franchise and potentially positions ziftomenib as a leading treatment in its class. Despite an anticipated near-term reduction in the stock's M&A premium, the deal is seen to enhance the company's fundamental value through a strengthened balance sheet and fully funded development in key AML markets.
Here are the latest investment ratings and price targets for $Kura Oncology (KURA.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月22日，多家华尔街大行更新了$Kura Oncology (KURA.US)$的评级，目标价介于18美元至34美元。
美银证券分析师Jason Zemansky维持买入评级，并将目标价从35美元下调至29美元。
巴克莱银行分析师Peter Lawson维持买入评级，维持目标价32美元。
富瑞集团分析师Roger Song维持买入评级，并将目标价从32美元下调至28美元。
TD Cowen分析师Phil Nadeau维持买入评级。
瑞穗证券分析师Salim Syed维持买入评级。
此外，综合报道，$Kura Oncology (KURA.US)$近期主要分析师观点如下：
kura oncology已与一家重要合作伙伴签订了一项重大的发展和商业化协议，涉及其主要项目ziftomenib。该协议除了包括可观的前期付款和值得关注的近期里程碑外，还为kura提供了坚实的财务基础，以推进关键性前线开发。这一战略合作伙伴关系为ziftomenib的广泛和积极的发展计划创造了条件，尤其是在急性髓系白血病的治疗方面，在关键时期最大限度地实现其商业潜力。此外，该协议减轻了与短中期公司股票相关的财务风险，同时保留了相当大的价值。
在kura oncology宣布与Kyowa Kirin达成全球战略联盟，共同开发和商业化ziftomenib，一种旨在治疗急性髓系白血病和其他血液系统恶性肿瘤的口服menin抑制剂之后，分析师将这项交易解读为具有战略优势。这为加快kura的AML特许经营提供了必要的资金，并有可能使ziftomenib成为其类别中的领先治疗方法。尽管预计股票的并购溢价会在近期出现下降，但这项交易被视为通过强化资产负债表和在关键AML市场中实现全资开发而增强了公司的基本价值。
以下为今日10位分析师对$Kura Oncology (KURA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
